EBIT: Income before interest and taxes.
ReShape Lifesciences Inc. (RSLS) had EBIT of $-1.76M for the most recently reported fiscal quarter, ending 2024-09-30.
| Income Statement Financials | |
$2.29M |
|
$-1.58M |
|
$0.85M |
|
$1.44M |
|
$4.05M |
|
$-1.76M |
|
$0.19M |
|
$-1.57M |
|
$-1.57M |
|
$-1.58M |
|
$-1.58M |
|
$-1.58M |
|
$-1.58M |
|
|
EBIT |
$-1.76M |
$-1.76M |
|
0.51M |
|
0.51M |
|
$-3.11 |
|
$-3.11 |
|
| Balance Sheet Financials | |
$5.34M |
|
$0.04M |
|
$0.28M |
|
$5.62M |
|
$4.03M |
|
-- |
|
$0.10M |
|
$4.13M |
|
$1.49M |
|
$1.49M |
|
$1.49M |
|
0.70M |
|
| Cash Flow Statement Financials | |
$-3.74M |
|
-- |
|
$0.02M |
|
$4.56M |
|
$0.84M |
|
$-3.72M |
|
$0.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
62.78% |
|
-76.83% |
|
-76.83% |
|
-- |
|
-68.72% |
|
-68.98% |
|
$-3.74M |
|
-- |
|
-- |
|
-- |
|
0.41 |
|
0.29 |
|
1.71 |
|
52.77 |
|
-106.32% |
|
-106.32% |
|
-28.16% |
|
-106.32% |
|
$2.11 |
|
$-7.35 |
|
$-7.35 |
|